Exploring The Future of Artificial Intelligence and Thoracic Oncology

Dr. Chinmay Jani discussed his involvement in precision oncology research initiatives, especially the use of AI–based tools in clinical oncology decision-making.
Findings from a study presented at the 2026 ASCO Annual Meeting revealed while AI systems aligned with experts in first-line treatment decisions for EGFR-mutated NSCLC, there was significant divergence in second-line decisions, necessitating rigorous validation and ethical safeguards.
Jani highlighted various research initiatives focused on precision medicine, immunotherapy resistance, and early cancer detection to better outcomes for lung cancer patients.
Emerging therapeutics such as tarlatamab-dlle (Imdelltra) and liquid biopsy techniques are being explored to manage lung cancer as a chronic disease, potentially allowing prolonged patient survival.
The evolving oncology landscape also addresses the needs of adolescent and young adult (AYA) patients, considering their unique molecular testing and therapeutic requirements.
Precision medicine advancements aim at identifying more fusions and alterations in cancer cells through methods such as broader use of circulating tumor DNA, RNA, and minimal residual disease testing.